Tempus AI Stock Soars on Collaboration with Follicular Lymphoma Institute, Attracts Major Institutional Investors

What's Going On With Tempus AI Shares Thursday? - Tempus AI (NASDAQ:TEM)

Tempus AI, Inc. TEM stock is trading higher on Thursday after the company announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI). What To Know: The collaboration aims to advance targeted therapy development for follicular lymphoma by creating a real-world multimodal data library within Tempus' data analytics platform. The collaboration will initially focus on generating data for POD24 patients who experience disease progression within 24 months of treatment. This resource will enable researchers to generate AI-driven insights that could accelerate treatment progress and improve patient outcomes. What Else: Tempus is expected to report earnings for the 2024 fiscal-year fourth-quarter on February 24 after the market closes. Analysts' estimate a loss of 20 cents per share and revenue of $203.12 million. Related Link: CyberArk Q4 Revenue Surges 41%, Subscription And Strong ARR Clock Strong Growth TEM Price Action: At the time of writing, Tempus shares are trading 14.5% higher at $84.60, according to data from Benzinga Pro. Image: Courtesy of Tempus AI TEMTempus AI Inc$84.8514.8%WatchlistOverviewMarket News and Data brought to you by Benzinga APIs

Tempus AI Stock Soars to All-Time High

A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism from Columbia University. Tempus AI (TEM) shares soared to an all-time high Thursday, extending their recent rally as the tech firm announced a collaboration with the nonprofit Institute for Follicular Lymphoma Innovation (IFLI) to develop targeted therapies for the disease. Tempus said its data analytics platform Lens will be used in the collaboration to help researchers "derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes." "We are excited to work with IFLI and explore a new way of working with foundations to advance research," said Tempus Chief Scientific Officer Kate Sasser, PhD. "By leveraging our combined expertise and reach, we aim to create a centralized and dynamic data library that enables researchers to better understand FL." Tempus shares were up nearly 15% to $84.85 Thursday afternoon after hitting an intraday record at $86. With Thursday's gains, they've surged nearly 50% so far this month, and more than doubled in value from their IPO price of $37 last June.

What the Options Market Tells Us About Tempus AI - Tempus AI (NASDAQ:TEM)

Investors with a lot of money to spend have taken a bearish stance on Tempus AI TEM. And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEM, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 48 uncommon options trades for Tempus AI. This isn't normal. The overall sentiment of these big-money traders is split between 43% bullish and 45%, bearish. Out of all of the special options we uncovered, 4 are puts, for a total amount of $156,020, and 44 are calls, for a total amount of $2,750,771. What's The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $120.0 for Tempus AI over the last 3 months. Volume & Open Interest Development Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you track the liquidity and interest for Tempus AI's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $20.0 to $120.0 in the last 30 days. Tempus AI 30-Day Option Volume & Interest Snapshot Noteworthy Options Activity: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume TEM CALL SWEEP BULLISH 03/21/25 $4.3 $4.1 $4.3 $110.00 $309.6K 1.7K 937 TEM CALL TRADE BULLISH 03/21/25 $6.0 $5.9 $6.0 $100.00 $300.0K 1.4K 2.8K TEM CALL SWEEP BEARISH 03/14/25 $11.2 $10.3 $10.2 $78.00 $203.9K 256 200 TEM CALL SWEEP BEARISH 02/28/25 $3.1 $2.7 $2.65 $98.00 $107.0K 3.6K 35 TEM CALL SWEEP BEARISH 02/28/25 $6.9 $6.7 $6.7 $90.00 $100.5K 1.9K 796 About Tempus AI Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. Present Market Standing of Tempus AI Trading volume stands at 11,609,211, with TEM's price up by 4.6%, positioned at $85.72. RSI indicators show the stock to be may be overbought. Earnings announcement expected in 5 days. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tempus AI options trades with real-time alerts from Benzinga Pro. TEMTempus AI Inc$86.415.44%WatchlistOverviewMarket News and Data brought to you by Benzinga APIs

Tempus AI Sees Surge In Institutional Holdings In Q4: Cathie Wood's Ark Invest, JPMorgan, And BlackRock Load Up On TEM Stock - Tempus AI (NASDAQ:TEM), Fidelity Nasdaq Composite Index ETF (NASDAQ:ONEQ)

Tempus AI Inc. TEM, an artificial intelligence-powered precision medicine solutions provider, which was listed on exchanges in June 2024 has seen major funds investing in the company during the fourth quarter of the year. What Happened: Tempus AI provides a two-pronged approach to healthcare. The first is an AI-driven precision medicine for personalized patient care, and the second one is a parallel engine for discovering, developing, and delivering optimal therapeutics. Over the three-quarters of 2024 for which the company has been listed, it has seen the number of filings grow to 174 from 89. Whereas, the number of shares, excluding options has also increased substantially. Here are a few key highlights of Tempus AI's fourth-quarter adjustments in the portfolios of various funds through its 13F SEC filings. Cathie Wood's ARK Investment Management LLC increased its position in the company by 132% from the third and 956% from the second quarter, with its current holdings in the company valued at $186.343 million. JPMorgan Chase & Co. added a staggering 43424% or 1,650,096 shares in the fourth quarter, whereas UBS Group AG increased its stake by 6524% or 786,025 shares in the same period. Barclays PLC also added 3675% or 34,031 shares of the company to its portfolio, while Goldman Sachs Group Inc. and Morgan Stanley hiked their stakes by 129% and 40%, respectively. BlackRock Inc., Bank of New York Mellon Corp., and Ken Griffin's Citadel Advisors LLC took fresh positions in Tempus AI and 70 other funds during the quarter. See Also: Billionaire Ray Dalio's Bridgewater Trims Holdings In 6 Of 'Magnificent 7' Stocks Amid Valuation Concerns, Adds This Automotive Stock After 3 Years Why It Matters: While filings and share counts grew substantially, the value of both shares and options experienced fluctuations and ultimately decreased in the fourth quarter. The data reveals notable trends across filings, shares, and their associated values from the second quarter to the fourth quarter of 2024. Indicating fewer option bets, the value of options, which peaked at $101 million in the third quarter, fell to $79.5 million in the fourth. However, despite the increase in common shares during the fourth quarter, the total value of shares (excluding options) decreased from $2.12 billion to $1.74 billion. Price Action: Tempus AI dropped 8.37% on Tuesday and recovered 1.21% during after-hours trading, contrasting with a slight 0.076% dip in the Fidelity NASDAQ Composite Index ETF ONEQ, which tracks the Nasdaq Composite index. Despite this recent fall, TEM remains up 139.27% on a year-to-date basis and 103.60% since its listing in June 2024. Benzinga tracks 11 analysts with an average price target of $59.6 for the stock, reflecting a "buy" rating. Estimates range widely from $44 to $74. Recent ratings from TD Cowen, Loop Capital, and Needham average $60.67, suggesting a potential 26.85% downside. Read Next: Jim Simons' Renaissance Technologies Makes AI Moves: Sells Big Tech, Buys Chinese Stocks, Robinhood In Q4 Photo courtesy: Tempus ONEQFidelity Nasdaq Composite Index ETF$78.850.01%WatchlistOverviewTEMTempus AI Inc$82.94-7.27%Market News and Data brought to you by Benzinga APIs